Impact Of Tisagenlecleucel Chimeric Antigen Receptor (Car)-T Cell Therapy Product Attributes On Clinical Outcomes In Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

BLOOD（2019）

引用 9|浏览1

暂无评分

摘要

Background: In the phase 2 JULIET trial, tisagenlecleucel, an anti-CD19 CAR-T cell therapy, demonstrated durable responses and manageable safety in adult patients (pts) with r/r DLBCL. Here, we examine the impact of key product cellular attributes of tisagenlecleucel on clinical outcomes.

查看译文

关键词

Refractory Diffuse Large B-Cell Lymphoma,Diffuse large B-cell lymphoma,Chimeric antigen receptor,Cell therapy,Cytokine release syndrome,Immunophenotyping,Human leukocyte antigen,Cancer research,Flow cytometry

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要